The core function of Cicloferon (Aciclovir) is to provide targeted therapeutic support for managing symptoms related to physical discomfort of infections caused by Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV). Its use is generally relevant in clinical settings marked by the heightened patient distress caused by these specific viral conditions.

The medicine may assist with easing pain and supports the healing of sores or blisters in people with conditions such as chickenpox, shingles, and initial or recurrent outbreaks of genital herpes and cold sores.

---

Targeted Treatment and Symptom Support

Cicloferon is commonly used in conditions characterized by episodic or fluctuating symptom patterns linked to HSV and VZV. Applied during the phase when symptoms are active or escalating, it is used for managing symptoms that may appear suddenly and may contribute to easing the overall symptom load and supports the patient during the episode. In this context, the focus is on managing symptoms related to physical discomfort associated with viral lesions.

Acute Discomfort and Recurrence Control

This medicine is used to ease the cluster of distressing manifestations known as prodromal symptoms (tingling, itching) and the resultant physical symptoms of acute pain, burning, and inflammation from the visible lesions. This provides support that helps patients cope more steadily with difficult episodes, contributing to day-to-day comfort during periods of heightened symptoms. Furthermore, it is applicable in conditions marked by the recurrent nature of the virus, where it is commonly used to help with suppressive therapy and may assist with maintaining functional stability by addressing recurrence.

Quick Fact: Support for Acute Pain and Tingling

---

Primary Indications Include: Herpes Simplex (Genital/Cold Sores), Herpes Zoster (Shingles), and Varicella (Chickenpox).

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Cicloferon?

This section describes the population eligibility rules for Cicloferon (Aciclovir), as defined by government regulatory authorities.

---

Absolute Contraindications

Cicloferon is contraindicated and must not be used by individuals with a known hypersensitivity to the active ingredient Aciclovir, Valaciclovir, or any of the inactive ingredients (excipients) found in the specific formulation. Additionally, specific oral forms may be contraindicated for patients with rare hereditary disorders such as galactose intolerance.

---

Eligibility Restrictions and Conditional Use

Certain populations are eligible for use but require special consideration and close monitoring:

• Impaired Renal Function: Use is restricted and requires a mandatory dose adjustment due to Aciclovir's dependence on the kidneys for elimination.
• Geriatric Patients: Individuals over 65 years old must be closely monitored and may require a reduced dose due to potential age-related decline in kidney function.
• Pregnancy and Lactation: Use during pregnancy is conditional, permitted only when the treating physician determines the potential benefit outweighs any potential risk. Caution is advised during breastfeeding, as Aciclovir passes into breast milk.

---

Age-Related Eligibility

For most oral forms, children over two years are eligible, though dosing is often weight-based or age-adjusted. For some topical creams, eligibility begins at 12 years of age. Use in infants and neonates typically requires specialized intravenous administration.

Cicloferon's official regulatory interaction profile is primarily defined by effects on renal clearance and the potential for additive toxicity, as documented in FDA and EMA product labels.

Pharmacokinetic Interactions

Co-administration with Probenecid (an antigout agent) or Cimetidine (an H₂-receptor antagonist) is documented to increase Aciclovir plasma exposure (Area Under the Curve, or AUC) and prolong its half-life. This effect is a pharmacokinetic interaction caused by these substances competing with Aciclovir for the active renal tubular secretion pathway, thereby reducing its elimination.

Similarly, co-administration with the immunosuppressant Mycophenolate Mofetil (MMF) results in a mutual increase in the plasma AUCs of both Aciclovir and MMF's inactive metabolite due to shared renal clearance mechanisms.

Exposure Modification and Monitoring

A separate pharmacokinetic interaction occurs with Theophylline (a methylxanthine), where Aciclovir co-therapy is officially shown to increase Theophylline AUC by approximately 50%. This mandates therapeutic plasma concentration monitoring during concomitant use.

Additive Toxicity Caution

Furthermore, a pharmacodynamic caution exists regarding Potentially Nephrotoxic Agents as a general class. Co-administering Cicloferon with such agents may increase the risk of renal dysfunction and the risk of reversible central nervous system symptoms. No specific drug-drug combinations are formally classified as contraindicated, and no mandatory timing requirements for dose separation are documented in the labels.

Selective Targeting and Activation by Viral Enzymes

The core mechanism relies on Aciclovir acting as a prodrug that must be activated by the virus itself. The drug is preferentially phosphorylated by the Viral Thymidine Kinase (TK), an enzyme expressed almost exclusively in infected cells. This enzyme-mediated step concentrates the active drug metabolite within the target cells.

Irreversible Blockade of Viral DNA Synthesis

Once fully activated, the drug metabolite acts as a molecular imposter. It competitively inhibits and incorporates into the growing strand of the Viral DNA, causing immediate chain termination because it lacks the necessary chemical structure to link the next building block. This action functionally paralyzes the Viral DNA Polymerase, completely shutting down the machinery responsible for creating new viral genomes.

Physiological Consequence and Constraint

By selectively and irreversibly halting the duplication of the viral genetic material, the drug arrests the viral reproductive cycle. This results in a profound physiological suppression of viral proliferation throughout the affected tissues. The mechanism is dependent on the presence of the Viral TK enzyme, meaning the activity is biologically constrained to the actively multiplying viral population and is unable to affect the dormant (latent) viral state.

How to Use Cicloferon

Cicloferon (Aciclovir) is administered through several routes depending on the severity and site of the viral infection. The most common routes are oral (using tablets, capsules, or suspension), topical (using cream or ointment), and intravenous (IV) infusion for more severe or systemic cases. Administration is aligned with the regimen prescribed in clinical guidelines, which establish specific instructions for timing and duration.

Official Administration Guidelines

Usage Constraint	Requirement
Initiation Timing	Treatment should be initiated as early as possible, ideally during the first signs of recurrence or within 24 hours of the onset of the rash or lesions.
Frequency	Acute oral treatment often requires five doses daily (e.g., 200 mg or 800 mg doses), while suppressive therapy is typically twice daily (e.g., 400 mg dose).
Duration	Course duration is strictly time-limited, typically ranging from 5 to 10 days for acute episodes. Suppressive therapy may be prolonged but often involves periodic re-evaluation.
Food Relationship	Oral forms of the medicine may be taken with or without food.
Hydration	Patients are instructed to maintain adequate hydration during treatment, particularly with high-dose oral or intravenous administration.

Population-Specific Dosing

Standard clinical practice involves dose adjustments for patients with impaired kidney function because the drug is primarily eliminated by the kidneys. For these patients, the dose and/or the interval between doses is modified according to measured Creatinine Clearance to prevent drug accumulation. Similarly, dose consideration is often noted for older adults due to the potential for reduced renal function in that population.

Research evidence / Overview of Studies for Cicloferon

Evidence for Use in Recurrent Herpes Labialis (Cold Sores)

Research exploring this condition, which is characterized by fluctuating or episodic manifestations, largely relies on controlled clinical trials. Studies primarily consisted of Randomized Controlled Trials (RCTs), where participants with a history of recurrent cold sores were randomly assigned to receive either the treatment or a non-active control (placebo). These studies were applied in research exploring how symptoms change over time and how they are measured during an acute episode.

Researchers focused on outcomes describing episodic or acute changes. This involved monitoring the time to complete lesion healing (e.g., time until the loss of crust) and measuring the duration of symptoms such as pain, tingling, or burning. Findings describe patterns observed in the studies: some trials reported measurements of the average time to healing and duration of pain for participants receiving the treatment compared to those receiving a placebo. However, research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Comparison of Cicloferon to Placebo and Other Treatments

Several studies explored how the topical treatment compared directly to a placebo gel. Research from these scenarios described patterns in the measured time-based outcomes, such as healing and symptom duration, in the groups that received the topical product. Reported findings indicated some variability in the measured time-based outcomes.

Other research examined comparisons of the topical treatment against different topical therapies or oral medication forms. Studies explored outcomes related to physical discomfort. Overall, the evidence describes symptom patterns, but comparative evidence is lacking for many head-to-head scenarios.

Long-Term Studies and Follow-Up Data

The research primarily focuses on the acute period of a cold sore episode. This means that the follow-up durations were limited, often extending only to the conclusion of the study observation period. Because of these limited follow-up durations, certainty remains low about long-term effects. Long-term outcomes, such as whether using the topical treatment over time was associated with a change in the frequency of future cold sore outbreaks, are not well characterized by the existing studies.

Evidence in Specific Patient Populations

Most of the available research that measured acute symptom changes was evaluated in immunocompetent adults and adolescents with a history of recurrent cold sores. Research exploring short-term symptom changes in other groups remains limited. Data for certain groups remain insufficient, including very young children or individuals with pre-existing conditions (comorbidities). While some studies have focused on systemic treatment forms of the active ingredient, those findings apply only to the populations studied and cannot be used to infer outcomes for the topical gel.

Common questions about Cicloferon (FAQ)

---

Q: How quickly does Cicloferon typically start working for its intended purpose?

A: Regulatory guidelines emphasize that treatment initiation is generally recommended as early as possible after the first signs appear to mitigate the condition. Clinical studies on the topical product measure time-based outcomes, such as the time to complete healing and the duration of symptoms. This data helps characterize the medicine's effect on the duration and severity of the condition.

Q: Are there any specific foods or drinks that should be avoided while using Cicloferon?

A: Official product information notes that oral forms of the medicine may be taken with or without food. Regulatory authorities also state that consuming alcohol is generally not documented to interfere with the way the medicine works. However, maintaining adequate hydration is particularly important during treatment, especially when taking high oral doses.

Q: Is it normal to feel a tingling sensation after applying Cicloferon?

A: Research trials monitor symptoms like tingling, pain, or burning as part of assessing the underlying condition. Separately, common local adverse reactions to the drug, as noted in regulatory documents, include effects such as pruritus (itching) and rashes.

Q: Is Cicloferon known to cause drowsiness or affect driving ability?

A: Regulatory documents state that the patient's clinical status and the adverse event profile are factors for consideration regarding driving or operating machinery. Drowsiness and somnolence (sleepiness) have been occasionally reported with the medicine, particularly in patients with kidney issues or those receiving higher doses.

Q: Does Cicloferon have a black box warning in the US or similar critical warning elsewhere?

A: The specific designation of a Black Box Warning is not featured for the oral forms in US regulatory documents (DailyMed). However, these documents do include prominent Warnings regarding serious risks, such as potential renal failure and rare haematological disorders.

Q: How do doctors monitor the effects of Cicloferon treatment?

A: Official labels instruct on monitoring for certain effects, especially when administering with other drugs or treating specific populations. For instance, patients with impaired renal function require professional monitoring of their kidney status, and concurrent use with Theophylline requires checking drug plasma levels.

Q: What does 'contraindication' mean regarding Cicloferon?

A: A contraindication is the official term for a condition or circumstance for which the medicine should be avoided due to a risk that outweighs the potential benefit. For Cicloferon, an absolute contraindication is a known hypersensitivity (severe allergy) to the active ingredient or any other substance (excipient) in the formulation.

Q: What is the evidence level (e.g., Phase III trials) supporting Cicloferon's use?

A: Research evidence supporting the medicine's use is predominantly based on data derived from Randomized Controlled Trials (RCTs). These trials represent a high level of evidence. The specific designation of a study as a Phase III trial is often used in the context of official drug approval documentation.

Q: Does Cicloferon interact with common pain relievers like ibuprofen?

A: According to formal drug interaction checkers based on regulatory data, no interaction has been documented between the active ingredient, Aciclovir, and the common pain reliever ibuprofen.

Q: Is Cicloferon known by any other brand names or generic names?

A: The active ingredient in Cicloferon is known chemically as Aciclovir, or by the alternative name Acycloguanosine. A common brand name mentioned in regulatory-affiliated sources, particularly in the US and UK, is Zovirax.

Q: Why is Cicloferon only available by prescription in some regions?

A: Prescription status is generally related to the need for professional monitoring of the risks associated with use. Regulatory documents highlight risks such as the potential for renal failure and the need for mandatory dosage adjustments based on specific patient conditions.

Q: Is Cicloferon a steroid medicine?

A: The medicine is officially classified as a synthetic purine nucleoside analogue and a direct acting antiviral. Based on its pharmacological classification, it is not a steroid medicine.

Q: If I miss an application of Cicloferon, what should be done?

A: Official patient guidance states that if a dose is missed, the dose is generally taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the patient continues with the regular schedule. Doses should not be doubled.

Q: What should I do if the side effects of Cicloferon feel worse than expected?

A: Official regulatory documents emphasize the importance of seeking professional evaluation if severe or troublesome adverse reactions are experienced. This ensures proper guidance and assessment of the symptoms.

Q: Is Cicloferon effective against all types of the condition it treats?

A: The inhibitory activity of the active ingredient is described in official documents as being highly selective against specific human herpes viruses. This includes HSV-1, HSV-2, and VZV.

Q: Does exposure to sunlight affect the use of Cicloferon?

A: The official adverse reaction profile includes photosensitive rash as a reported event in the skin and subcutaneous tissue disorders category. This is noted as a possibility for users of the medicine.

Q: Are there guidelines for stopping the use of Cicloferon?

A: Official guidelines indicate that the medicine is used for the full prescribed time or until professional guidance is given. For some specific topical uses, regulatory guidance may specify stopping if the affected area has not healed after 10 days.

Q: What should I do if I accidentally get Cicloferon in my eye?

A: Specific official warnings are provided regarding application areas for the topical cream. The official warnings explicitly state that the cream should not be put in the eyes.

Q: Can I use other topical products at the same time as Cicloferon?

A: Official labels for the topical ointment state that clinical experience has identified no interactions resulting from topical or systemic administration of other drugs concomitantly with the ointment. There are no mandatory timing requirements for dose separation documented in the labels.

Q: What is the role of the inactive ingredients in the Cicloferon formulation?

A: The official labels list the inactive ingredients (excipients), which are components such as microcrystalline cellulose and magnesium stearate. These ingredients primarily serve non-medicinal functions like providing structure, binding, or preservation to the medicine.

Q: Are there any lifestyle changes that enhance the effectiveness of Cicloferon?

A: Official information emphasizes that maintaining adequate hydration is particularly important when taking high oral doses. Some patient advice also suggests trying to avoid or manage stress as a potential trigger for the underlying condition being treated.

Q: What is the difference between Cicloferon cream and Cicloferon ointment?

A: Regulatory documents describe the cream and ointment forms separately, noting they contain different inactive ingredients (excipients). Both forms result in minimal systemic absorption (entry into the bloodstream), but the formulations differ in their specific composition and skin properties.

Q: Why is consistency in application often mentioned for Cicloferon?

A: Consistency in application is related to the drug's mechanism of action. The medicine must be applied frequently enough to maintain the necessary concentration in the infected cells to effectively inhibit viral DNA replication, thereby arresting the reproductive cycle of the virus.

Storage and Disposal of Cicloferon (Aciclovir)

Official regulatory documents define specific storage and handling requirements for Cicloferon (Aciclovir) to ensure product stability. All forms of the medicine must be stored out of the sight and reach of children.

Mandatory Storage Conditions

Form	Required Temperature Range	Protection Rules
Tablets	20°C to 25°C (68°F to 77°F)	Protect from light and moisture.
Suspension/Cream	15°C to 25°C (59°F to 77°F)	Do not freeze the suspension.

All oral forms should be kept in a tightly closed and light-resistant container. Disposal of unused or expired product must follow local regulatory requirements; medicine should not be disposed of via household waste or wastewater unless specifically instructed. Used needles and sharps from the injection form require a dedicated sharps disposal container.